Navigation Links
Exhaustive Study to Expand the Efficacy of Drug L-dopa for Parkinson's

Parkinson's sufferers are usually treated with the drug called levodopa or L-dopa that helps in reviving cellular communication//. After prolonged use of the drug, many patients may experience motor complications and a reduced response to the drug.

Parkinson's disease is a slow process of destruction of brain cells which produce dopamine. As dopamine levels fall, the symptoms of Parkinson’s shows up as tremors in the arms, legs and face. The patients visibly portray slow movement, lack of proper balance and coordination.

A new clinical trial is underway to evaluate the effectiveness of a novel drug to treat Parkinson’s, which could extend the benefits of he existing drug, L-dopa. The study will also investigate the potential of the drug, E2007, and its contribution in extending the effectiveness of L-dopa.

The prevailing treatment for Parkinson's disease aims to revive cellular communication by simply restoring the lost dopamine with L-dopa. Though this therapy is effective for sometime, yet it is unable to halt the gradual decline so evident in long time Parkinson’s sufferers.

"The hope is that by altering dopamine transmission through the modulating the activity of AMPA receptors, there will be measurable effects on the dopamine system," said Dr. Liang.

The study has been tailored to suit patients suffering advanced Parkinson's and have been undergoing L-dopa treatment for a considerable period of time. The study will involve nearly 700 patients from more than 100 centers across the U.S., Canada, Australia, New Zealand and South America.

Dr. Kremens said, "It's an interesting approach and an exciting trial because it is exploring a drug in a new therapeutic category. L-dopa is still the gold standard and we haven't come up with a better dopamine as yet."
'"/>




Page: 1

Related medicine news :

1. Dolly Paves the Way for Exhaustive Stem Cell Research
2. Cancer Drug Helps An Anti-Cancer Virus To Act More Exhaustively
3. Tomato Sauce reduces Cancer Risk- Study
4. Study on obesity and heart failure
5. National Lung Study in the process
6. Study casts doubt on keyboard ills
7. Study reveals how stress can make you sick
8. Study reveals how stress can make you sick
9. Study supports vegetable diet
10. Study to look at early surgery to treat epilepsy
11. Its Never Too Late to Stop Smoking,Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... insurance and financial consultation services to residents in the Sacramento/Folsom region, is initiating ... Chance treatment facility. , The Another Choice Another Chance treatment center in Sacramento ...
(Date:12/7/2016)... ... 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering ... is launching a charity drive to raise funds that will benefit the Marine Corps ... marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann ...
(Date:12/7/2016)... ... ... Facial plastic surgeon, Dr. John D. Rachel of Timeless You™ Chicago , ... local organizations: North Chicago Animal Control and Friends and Our House of Hope Rescue. ... and trained volunteers who support rescued animals held in the City of North Chicago’s ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware ... One major study analyzing heart attacks among 138,602 people recorded a 35% higher ... year. We would all agree of course–no time of year is a good time ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... 7, 2016 Boehringer Ingelheim today announced ... with unresectable malignant pleural mesothelioma (MPM) met its ... presented at the 17 th IASLC World ... , showed nintedanib plus pemetrexed/cisplatin demonstrated a ... with a significantly improved PFS (9.4 vs 5.7 ...
(Date:12/7/2016)... , December 7, 2016 Today, Stock-Callers.com ... (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ... ), and AveXis Inc. (NASDAQ: AVXS ). From ... fell roughly 37% to reach a level equal to what ... down by approximately 14% for the year, it has still ...
Breaking Medicine Technology: